| Title |
Identification of PPARγ ligands with One-dimensional Drug Profile Matching
|
|---|---|
| Published in |
Drug Design, Development and Therapy, September 2013
|
| DOI | 10.2147/dddt.s47173 |
| Pubmed ID | |
| Authors |
Diána Kovács, Zoltán Simon, Péter Hári, András Málnási-Csizmadia, Csaba Hegedűs, László Drimba, József Németh, Réka Sári, Zoltán Szilvássy, Barna Peitl |
| Abstract |
Computational molecular database screening helps to decrease the time and resources needed for drug development. Reintroduction of generic drugs by second medical use patents also contributes to cheaper and faster drug development processes. We screened, in silico, the Food and Drug Administration-approved generic drug database by means of the One-dimensional Drug Profile Matching (oDPM) method in order to find potential peroxisome proliferator-activated receptor gamma (PPARγ) agonists. The PPARγ action of the selected generics was also investigated by in vitro and in vivo experiments. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 27 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 4% |
| Unknown | 26 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 6 | 22% |
| Researcher | 5 | 19% |
| Student > Doctoral Student | 2 | 7% |
| Student > Bachelor | 2 | 7% |
| Lecturer > Senior Lecturer | 2 | 7% |
| Other | 5 | 19% |
| Unknown | 5 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 8 | 30% |
| Computer Science | 3 | 11% |
| Agricultural and Biological Sciences | 3 | 11% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 7% |
| Chemistry | 2 | 7% |
| Other | 6 | 22% |
| Unknown | 3 | 11% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 December 2013.
All research outputs
#20,110,957
of 25,584,565 outputs
Outputs from Drug Design, Development and Therapy
#1,299
of 2,254 outputs
Outputs of similar age
#155,414
of 212,862 outputs
Outputs of similar age from Drug Design, Development and Therapy
#26
of 48 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. This one is in the 18th percentile – i.e., 18% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,254 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.3. This one is in the 37th percentile – i.e., 37% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 212,862 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 24th percentile – i.e., 24% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 48 others from the same source and published within six weeks on either side of this one. This one is in the 45th percentile – i.e., 45% of its contemporaries scored the same or lower than it.